Breast Cancer Tumor Care Observational Programme
- Registration Number
- NCT00660244
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to investigate efficacy and tolerability under anastrozole (Arimidex) treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 150
Inclusion Criteria
- Postmenopausal women
- Already on upfront Arimidex Therapy (Start 1-4 weeks before)
- HR+
Exclusion Criteria
- Premenopausal women
- Tamoxifen switch patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 anastrozole -
- Primary Outcome Measures
Name Time Method Progression of disease and tolerability in general Baseline, every 3 month
- Secondary Outcome Measures
Name Time Method Patient questionnaire to collect data on Incidence, time of onset and treatment of arthralgia Baseline, every 3 month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie anastrozole's efficacy in postmenopausal breast cancer patients with arthralgia?
How does anastrozole compare to other aromatase inhibitors in managing postmenopausal breast cancer symptoms and recurrence rates?
Which biomarkers correlate with response to anastrozole in postmenopausal breast cancer patients experiencing arthralgia?
What adverse event management strategies are effective for anastrozole-induced arthralgia in postmenopausal breast cancer patients?
How do AstraZeneca's anastrozole studies inform combination therapies for postmenopausal breast cancer with aromatase inhibitor resistance?
Trial Locations
- Locations (1)
Research Site
🇦🇹Graz, Austria
Research Site🇦🇹Graz, Austria